Financial reports
10-Q
2024 Q2
Quarterly report
13 Aug 24
10-Q
2024 Q1
Quarterly report
7 May 24
ARS
2023 FY
Annual report to shareholders
22 Apr 24
10-K
2023 FY
Annual report
26 Mar 24
10-Q
2023 Q3
Quarterly report
7 Nov 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
10-Q
2023 Q1
Quarterly report
10 May 23
ARS
2022 FY
Annual report to shareholders
27 Apr 23
10-K
2022 FY
Annual report
21 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
Current reports
8-K
Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927
17 Sep 24
8-K
Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business Update
13 Aug 24
8-K
Vigil Neuroscience Announces Interim Data from its Ongoing Phase 1 Clinical Trial Evaluating VG-3927
24 Jul 24
8-K
Vigil Neuroscience Provides Update on Clinical Development Strategy to Pursue Potential Accelerated
18 Jul 24
8-K
Vigil Neuroscience Announces $40 Million Strategic Investment from Sanofi
27 Jun 24
8-K
Amendments to Articles of Incorporation or Bylaws
6 Jun 24
8-K
Vigil Neuroscience Reports First Quarter 2024 Financial Results and Provides Business Update
7 May 24
8-K
Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
26 Mar 24
8-K
Regulation FD Disclosure
11 Jan 24
8-K
Regulation FD Disclosure
16 Nov 23
Registration and prospectus
S-8
Registration of securities for employees
26 Mar 24
S-8
Registration of securities for employees
21 Mar 23
S-3
Shelf registration
21 Mar 23
S-1
IPO registration
30 Sep 22
D
$75M in equity / options / securities to be acquired, sold $75M, 9 investors
29 Aug 22
S-8
Registration of securities for employees
10 Jan 22
424B4
Prospectus supplement with pricing info
10 Jan 22
8-A12B
Registration of securities on exchange
4 Jan 22
S-1/A
IPO registration (amended)
3 Jan 22
S-1
IPO registration
19 Nov 21
Proxies
DEFA14A
Additional proxy soliciting materials
22 Apr 24
DEF 14A
Definitive proxy
22 Apr 24
PRE 14A
Preliminary proxy
12 Apr 24
DEFA14A
Additional proxy soliciting materials
9 May 23
DEFA14A
Additional proxy soliciting materials
27 Apr 23
DEF 14A
Definitive proxy
27 Apr 23
DEFA14A
Additional proxy soliciting materials
28 Apr 22
DEF 14A
Definitive proxy
28 Apr 22
Other
UPLOAD
Letter from SEC
5 Sep 23
CORRESP
Correspondence with SEC
31 Aug 23
UPLOAD
Letter from SEC
25 Aug 23
EFFECT
Notice of effectiveness
31 Mar 23
CORRESP
Correspondence with SEC
28 Mar 23
UPLOAD
Letter from SEC
27 Mar 23
UPLOAD
Letter from SEC
28 Feb 23
EFFECT
Notice of effectiveness
17 Oct 22
CORRESP
Correspondence with SEC
12 Oct 22
UPLOAD
Letter from SEC
11 Oct 22
Ownership
SC 13D/A
Vida Ventures GP III, L.L.C.
9 Oct 24
144
Notice of proposed sale of securities
19 Sep 24
SC 13G
Invus Global Management, LLC
12 Aug 24
4
Stefan Vitorovic
7 Jun 24
4
Mary Thistle
7 Jun 24
4
Suzanne Louise Bruhn
7 Jun 24
4
Gerhard Koenig
7 Jun 24
4
Bruce Booth
7 Jun 24
4
Haeberlein Samantha L. Budd
7 Jun 24
4
Cheryl R Blanchard
7 Jun 24